Mode
Text Size
Log in / Sign up

First-line platinum-based chemotherapy associated with disease control and survival in recurrent NSCLC patientsChemotherapy Changes Your Immune Cells

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider peripheral TCRβ profiling as an exploratory biomarker for NSCLC response, warranting prospective validation.

This single-arm cohort study enrolled 42 patients with recurrent unresectable locally advanced or stage IV non-small cell lung cancer (NSCLC) lacking actionable mutations. All participants received first-line platinum-based chemotherapy at Ramathibodi Hospital. Assessments occurred at baseline (T1), chemotherapy completion (T2), and confirmed disease progression (T3). The primary outcomes included disease control and overall survival, while secondary outcomes examined TCRβ repertoire dynamics, including Shannon diversity, Pielou evenness, TCR convergence frequency, unique clone counts, and principal component analysis (PCA) of clonal frequencies.

Disease control was achieved in 11 of 15 patients evaluated at T2 (73%). Longitudinal attrition occurred in 74% of patients prior to T2 due to death, compared to 27% in others (p=0.014). Among patients reaching T2, those with disease control demonstrated significantly smaller declines in unique clone counts (-16% versus -41%; Wilcoxon p=0.020, q=0.030). Additionally, TCR convergence frequency trended higher in disease control patients (0.0040 versus 0.0023). PCA revealed compact repertoire clustering in disease control versus wide PC2 dispersion in progressive disease (p=0.030, q=0.030). In patients reaching T3, rises in Shannon diversity and convergence observed post-chemotherapy reversed at progression.

Overall survival was significantly longer in patients achieving disease control (log-rank p=0.036). No safety data, adverse events, discontinuations, or tolerability information were reported. The study acknowledges limitations regarding longitudinal attrition driven primarily by pre-T2 death and the fact that TCR repertoire impact remains poorly characterized. No funding or conflicts of interest were reported.

The study suggests that peripheral TCRβ profiling may serve as an exploratory biomarker for monitoring treatment response in NSCLC, though these findings warrant prospective validation before clinical integration.

Imagine your body as a fortress with millions of unique guards watching for invaders. In lung cancer, these guards often fail to stop the disease. But new research shows that standard chemotherapy might actually reshape this guard force in a surprising way.

Lung cancer is one of the most common cancers worldwide. Many patients have advanced disease that cannot be removed with surgery. For these people, doctors usually rely on drugs called chemotherapy.

These drugs kill fast-growing cancer cells. But they also affect healthy cells. Doctors have long worried that chemotherapy weakens the immune system. This fear makes patients hesitant to use these powerful treatments.

The Surprising Shift

For years, scientists thought chemotherapy only damaged the immune system. They believed it wiped out the "guards" without replacing them. This view made many patients feel helpless against the disease.

But here's the twist. A new study from Thailand found something different. Chemotherapy does change the immune system. However, it doesn't always destroy it. Sometimes, it helps the body organize its defenses better.

What Scientists Didn't Expect

Think of your immune system like a library. Each book represents a unique way to fight a specific threat. A healthy library has many different books. If you lose too many books, you can't fight new threats.

Chemotherapy was thought to burn down the whole library. This study looked closely at the books after treatment. They found that some patients kept their collection organized. Their immune system stayed diverse and ready to fight.

The researchers looked at a specific part of the immune system called T-cells. These cells recognize cancer and attack it. They used a special test to count the different types of T-cells.

They found two key signs of a strong immune response. First, the variety of T-cells stayed high. Second, the immune system focused on a few strong fighters. This focus is like a team concentrating on one enemy instead of being spread too thin.

The team studied 42 patients with advanced lung cancer. These patients had no other treatment options available. They received standard chemotherapy without additional immune drugs.

Doctors took blood samples at three times. They checked the immune system before treatment, after treatment, and when the cancer grew back. This timeline showed how the immune system changed over time.

The most important result was about stability. Patients who did well with treatment kept a stable immune profile. Their immune system didn't lose too many unique fighters.

Patients whose cancer progressed lost many unique fighters. Their immune system became less diverse. This loss happened quickly after chemotherapy finished.

This doesn't mean this treatment is available yet.

The study also looked at the big picture. Patients with a stable immune system lived longer. This connection suggests that how your immune system responds to drugs predicts your outcome. It is a sign of how well the treatment is working.

Doctors see many patients with advanced lung cancer every day. Current treatments often run out of options. Finding a way to predict success is vital for patient care.

This research offers a new way to look at chemotherapy. It suggests that the drug does more than just kill cancer cells. It also shapes the immune system in a measurable way.

If you or a loved one has lung cancer, talk to your doctor about your immune health. Knowing how your body responds to treatment can help plan the next steps.

This is not a new drug. It is a new way to understand existing drugs. You do not need to change your treatment plan today. But understanding these signs can help doctors make better choices.

This study had some limits. It only included patients at one hospital. The number of people was small. Also, the study did not include patients who got other types of cancer drugs.

These factors mean the results need more testing. Scientists must check if this works for other patients in different places.

More research is needed to confirm these findings. Large studies will check if this pattern holds true everywhere. Doctors may use these signs to choose the best treatment faster.

Until then, chemotherapy remains a key tool. Understanding its effects on the immune system gives hope. It shows that even in tough cases, the body can find ways to fight back.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
Cytotoxic chemotherapy can modulate antitumor immunity, yet its impact on the peripheral T-cell receptor (TCR) repertoire in non-targetable advanced NSCLC remains poorly characterized. We prospectively investigated chemotherapy-induced TCRβ repertoire dynamics and their prognostic relevance. Patients with recurrent unresectable locally advanced or stage IV NSCLC without actionable mutations received first-line platinum-based chemotherapy (no immunotherapy) at Ramathibodi Hospital (2021–2024). Peripheral blood was collected at baseline (T1), chemotherapy completion (T2), and confirmed disease progression (T3). TCRβ sequencing (Ion Torrent™ Oncomine™ TCR Beta-LR) was performed on samples rarefied to >1.5 million reads. Shannon diversity, Pielou evenness, TCR convergence frequency, unique clone counts, and principal component analysis (PCA) of clonal frequencies were analyzed. Multiple comparisons were Benjamini–Hochberg corrected (significance: p Of 42 enrolled patients, 34 were T1-evaluable and 15 at T2; longitudinal attrition was driven primarily by pre-T2 death (74% vs. 27%; p=0.014). Disease control was achieved in 11/15 T2-evaluable patients (73%). Disease control patients trended higher TCR convergence (0.0040 vs. 0.0023) and significantly smaller decline in unique clone counts (−16% vs. −41%; Wilcoxon p=0.020, q=0.030). PCA revealed compact repertoire clustering in disease control versus wide PC2 dispersion in progressive disease (PD) patients (p=0.030, q=0.030). Among 4 patients reaching T3 (all PD), post-chemotherapy rises in Shannon diversity and convergence reversed at T3, consistent with immune attrition. Overall survival was significantly longer in disease control patients (log-rank p=0.036). Stable clonal convergence and preserved clone counts associate with disease control and survival in non-targetable advanced NSCLC receiving chemotherapy, supporting peripheral TCRβ profiling as an exploratory biomarker warranting prospective validation.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.